WO2008156012A1 - モータリン siRNAを含む癌治療剤 - Google Patents

モータリン siRNAを含む癌治療剤 Download PDF

Info

Publication number
WO2008156012A1
WO2008156012A1 PCT/JP2008/060599 JP2008060599W WO2008156012A1 WO 2008156012 A1 WO2008156012 A1 WO 2008156012A1 JP 2008060599 W JP2008060599 W JP 2008060599W WO 2008156012 A1 WO2008156012 A1 WO 2008156012A1
Authority
WO
WIPO (PCT)
Prior art keywords
mortalin
sirna
remedy containing
cancer remedy
cancer
Prior art date
Application number
PCT/JP2008/060599
Other languages
English (en)
French (fr)
Inventor
Renu Wadhwa
Sunil Kaul
Chae-Ok Yun
Original Assignee
National Institute Of Advanced Industrial Science And Technology
Yonsei University Industry-Academic Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute Of Advanced Industrial Science And Technology, Yonsei University Industry-Academic Cooperation Foundation filed Critical National Institute Of Advanced Industrial Science And Technology
Priority to JP2009520437A priority Critical patent/JP5625143B2/ja
Publication of WO2008156012A1 publication Critical patent/WO2008156012A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本発明は、配列番号１から６の何れかに記載の塩基配列を標的配列とするｓｉＲＮＡ又はｓｈＲＮＡに関する。本発明によれば、モータリン shRNA を利用した抗癌剤を提供することができる。
PCT/JP2008/060599 2007-06-20 2008-06-10 モータリン siRNAを含む癌治療剤 WO2008156012A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009520437A JP5625143B2 (ja) 2007-06-20 2008-06-10 モータリンｓｉＲＮＡを含む癌治療剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007162029 2007-06-20
JP2007-162029 2007-06-20

Publications (1)

Publication Number Publication Date
WO2008156012A1 true WO2008156012A1 (ja) 2008-12-24

Family

ID=40156170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/060599 WO2008156012A1 (ja) 2007-06-20 2008-06-10 モータリン siRNAを含む癌治療剤

Country Status (3)

Country Link
JP (1) JP5625143B2 (ja)
KR (1) KR101555926B1 (ja)
WO (1) WO2008156012A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040819A2 (en) * 2007-09-25 2009-04-02 Ramot At Tel Aviv University Ltd. DOWN-REGULATION OF MORTALIN BY siRNA
WO2011065677A2 (ko) * 2009-11-30 2011-06-03 한국생명공학연구원 암 치료용 약학 조성물
US8293716B2 (en) 2005-05-26 2012-10-23 Ramot At Tel Aviv University Ltd. Method of treating cancer by modulation of mortalin
JP2016539084A (ja) * 2013-10-02 2016-12-15 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド 転移を阻害し、線維症を処置し、かつ創傷の治癒を向上させる方法および組成物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013115579A1 (ko) * 2012-01-31 2013-08-08 연세대학교 산학협력단 ＴＧＦ－β２ 발현을 억제하는 ｓｈＲＮＡ
KR20170081962A (ko) 2016-01-05 2017-07-13 한양대학교 산학협력단 켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006089471A (ja) * 2004-08-26 2006-04-06 National Institute Of Advanced Industrial & Technology 癌の治療における抗モータリン２抗体と機能性核酸の使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006089471A (ja) * 2004-08-26 2006-04-06 National Institute Of Advanced Industrial & Technology 癌の治療における抗モータリン２抗体と機能性核酸の使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM E. ET AL.: "Ad-mTERT-delta19, a Conditional Replication-Competent Adenovirus Driven by the Human Telomerase Promoter, Selectively Replicates in an Elicits Cytopathic Effect in a Cancer Cell-Specific Manner", HUMAN GENE THERAPY, vol. 14, 2003, pages 1415 - 1428, XP008057972 *
MIYAGISHI M. ET AL.: "U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells", NATURE BIOTECHNOLOGY, vol. 19, no. 5, 2002, pages 497 - 500, XP001153719 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293716B2 (en) 2005-05-26 2012-10-23 Ramot At Tel Aviv University Ltd. Method of treating cancer by modulation of mortalin
WO2009040819A2 (en) * 2007-09-25 2009-04-02 Ramot At Tel Aviv University Ltd. DOWN-REGULATION OF MORTALIN BY siRNA
WO2009040819A3 (en) * 2007-09-25 2009-05-28 Univ Ramot DOWN-REGULATION OF MORTALIN BY siRNA
US8470793B2 (en) 2007-09-25 2013-06-25 Ramot At Tel-Aviv University Ltd. Down-regulation of mortalin by siRNA
WO2011065677A2 (ko) * 2009-11-30 2011-06-03 한국생명공학연구원 암 치료용 약학 조성물
WO2011065677A3 (ko) * 2009-11-30 2011-11-03 한국생명공학연구원 암 치료용 약학 조성물
US8846630B2 (en) 2009-11-30 2014-09-30 Korea Research Institute Of Bioscience And Biotechnology Pharmaceutical composition for treating cancer
US9217149B2 (en) 2009-11-30 2015-12-22 Korea Research Institute Of Bioscience And Biotechnology Pharmaceutical composition for treating cancer
JP2016539084A (ja) * 2013-10-02 2016-12-15 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド 転移を阻害し、線維症を処置し、かつ創傷の治癒を向上させる方法および組成物
US10894961B2 (en) 2013-10-02 2021-01-19 Albert Einstein College Of Medicine Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing
US11028391B2 (en) 2013-10-02 2021-06-08 Albert Einstein College Of Medicine Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing

Also Published As

Publication number Publication date
JPWO2008156012A1 (ja) 2010-08-26
KR20100066429A (ko) 2010-06-17
KR101555926B1 (ko) 2015-09-25
JP5625143B2 (ja) 2014-11-19

Similar Documents

Publication Publication Date Title
PH12015501953A1 (en) Substituted nucleotide analogs
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
IN2012DN02092A (ja)
WO2008152131A3 (en) Rnai inhibition of alpha-enac expression
MX2012002434A (es) Conjugados de dimeros de pirrolo[1,4] benzodiazepina como agentes anticacerosos.
NZ588884A (en) Cross-linkers and their uses
WO2008154249A3 (en) Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2010003520A3 (en) Anti-tumor immunotherapy
WO2012139039A3 (en) Bisphenol compounds and methods for their use
WO2012134918A3 (en) Friendly funding source
WO2008156012A1 (ja) モータリン siRNAを含む癌治療剤
EA201000974A1 (ru) Способ усиления иммунореактивности
RU2012147589A (ru) Новые отдельные химические структурные единицы и способы доставки олигонуклеотидов
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
MX2009008660A (es) Metodo para la preparacion de derivados de trifenilbuteno terapeuticamente valiosos.
WO2009030884A3 (en) Mannosylated butyrophilin tumour markers
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
MX339300B (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos.
WO2012075117A3 (en) Small molecule-polymer conjugates and methods of making same
WO2022084331A3 (en) Novel ligands for asialoglycoprotein receptor
MX2009009490A (es) Profarmacos novedosos.
MX2013005450A (es) Polimeros terminados en carbinol que contienen eter.
WO2010117979A3 (en) Serotonin and norepinephrine reuptake inhibitor
AR066416A1 (es) Catalizador de deshidrogenacion, proceso de preparacion del mismo y proceso de deshidrogenacion de un hidrocarburo

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08765388

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009520437

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107000581

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 08765388

Country of ref document: EP

Kind code of ref document: A1